Enanta Pharmaceuticals (ENTA) Net Income towards Common Stockholders (2012 - 2026)

Enanta Pharmaceuticals' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at -$13.1 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 42.19% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$62.0 million (up 35.71% YoY) and the FY2025 annual result came in at -$81.9 million, up 29.43% from the prior year.
• Net Income towards Common Stockholders was -$13.1 million for Q1 2026 at Enanta Pharmaceuticals, down from -$11.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$11.9 million in Q4 2025 and bottomed at -$39.1 million in Q2 2023.
• A 5-year average of -$26.2 million and a median of -$26.3 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 67.83% in 2022, while the deepest fall reached 31.95% in 2022.
• Enanta Pharmaceuticals' Net Income towards Common Stockholders stood at -$29.0 million in 2022, then dropped by 15.25% to -$33.4 million in 2023, then jumped by 33.28% to -$22.3 million in 2024, then jumped by 46.44% to -$11.9 million in 2025, then declined by 9.66% to -$13.1 million in 2026.
• Business Quant data shows ENTA's Net Income towards Common Stockholders at -$13.1 million in Q1 2026, -$11.9 million in Q4 2025, and -$18.7 million in Q3 2025.